問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

MacKay Memorial Hospital

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間:2023-09-19

顏志軒
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

21Cases

2025-03-01 - 2030-06-30

Active
A phase III, randomized, double-blind, placebo-controlled, event-driven trial was conducted to evaluate the effect of Baxdrostat in combination with Dapagliflozin compared to Dapagliflozin alone on the risk of first-time heart failure and cardiovascular death in participants at high risk of developing heart failure.
  • Condition/Disease

    The time elapsed before the first occurrence of any of the following events: • Hospitalization due to HF • Non-hospitalized HF • Death due to CV

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites

2025-07-01 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2024-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
20Sites

Not yet recruiting11Sites

Recruiting8Sites

2024-04-01 - 2026-09-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2006-02-01 - 2006-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2021-05-18 - 2023-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites

2022-01-19 - 2027-10-20

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2026-05-11 - 2030-01-07

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2025-10-01 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

1 2 3